An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks af­ter bag­ging $80 mil­lion in a deal to col­lab­o­rate with Gingko Bioworks on its spe­cial blend of en­gi­neered bac­te­ria used for “liv­ing ther­a­peu­tics,” lit­tle Syn­log­ic in Boston $SYBX is toss­ing one of its two clin­i­cal pro­grams af­ter watch­ing an ear­ly-stage study go down in de­feat.

Their Phase Ib/IIa study for SYNB1020 to counter the ac­cu­mu­la­tion of am­mo­nia in the body, a con­di­tion called hy­per­am­mone­mia or urea cy­cle dis­or­der, floun­dered at the in­ter­im read­out, forc­ing the biotech to kill it and re­serve its cash for pipeline ther­a­pies with greater po­ten­tial.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.